Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online May 17, 2007
Stem Cells Vol. 25 No. 8 August 2007, pp. 1966 -1974
doi:10.1634/stemcells.2007-0167; www.StemCells.com
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2007-0167v1
25/8/1966    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaganathan, B. G.
Right arrow Articles by Henschler, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaganathan, B. G.
Right arrow Articles by Henschler, R.

THE STEM CELL NICHE

Rho Inhibition Induces Migration of Mesenchymal Stromal Cells

Bithiah Grace Jaganathana, Brigitte Ruestera, Lars Dressela, Stefan Steinb, Manuel Grezb, Erhard Seifrieda, Reinhard Henschlera

aInstitute of Transfusion Medicine and Immune Hematology, German Red Cross Blood Donor Service, University of Frankfurt, Frankfurt am Main, Germany;
bChemotherapeutic Research Institute Georg Speyer Haus, Frankfurt, Germany

Key Words. Rho GTPases • Actin • Chemotaxis • Migration • Mesenchymal stem cells

Correspondence: Reinhard Henschler, M.D., Institute of Transfusion Medicine and Immune Hematology, University Hospital Frankfurt, Sandhofstrasse 1, D 60528 Frankfurt, Germany. Telephone: +49 69 6782 191; Fax: +49 69 6782 258; e-mail: rhenschler{at}web.de

Received on March 8, 2007; accepted for publication on May 3, 2007.

First published online in STEM CELLS EXPRESS  May 17, 2007.


Although mesenchymal stromal cells (MSCs) are being increasingly used as cell therapeutics in clinical trials, the mechanisms that regulate their chemotactic migration behavior are incompletely understood. We aimed to better define the ability of the GTPase regulator of cytoskeletal activation, Rho, to modulate migration induction in MSCs in a transwell chemotaxis assay. We found that culture-expanded MSCs migrate poorly toward exogenous phospholipids lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) in transwell assays. Moreover, plasma-induced chemotactic migration of MSCs was even inhibited after pretreatment with LPA. LPA treatment activated intracellular Rho and increased actin stress fibers in resident MSCs. Very similar cytoskeletal changes were observed after microinjection of a cDNA encoding constitutively active RhoA (RhoAV14) in MSCs. In contrast, microinjection of cDNA encoding Rho inhibitor C3 transferase led to resolution of actin stress fibers, appearance of a looser actin meshwork, and increased numbers of cytoplasmic extensions in the MSCs. Surprisingly, in LPA-pretreated MSCs migrating toward plasma, simultaneous addition of Rho inhibitor C2I-C3 reversed LPA-induced migration suppression and led to improved migration. Moreover, addition of Rho inhibitor C2I-C3 resulted in an approximately 3- to 10-fold enhancement of chemotactic migration toward LPA, S1P, as well as platelet-derived growth factor or hepatocyte growth factor. Thus, inhibition of Rho induces rearrangement of actin cytoskeleton in MSCs and renders them susceptible to induction of migration by physiological stimuli.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
M. Komachi, H. Tomura, E. Malchinkhuu, M. Tobo, C. Mogi, T. Yamada, T. Kimura, A. Kuwabara, H. Ohta, D.-S. Im, et al.
LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites
Carcinogenesis, March 1, 2009; 30(3): 457 - 465.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
K Yamahara, K D Min, H Tomoike, K Kangawa, S Kitamura, and N Nagaya
Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation
Heart, February 1, 2009; 95(4): 283 - 289.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2007 by AlphaMed Press.